Respiratory syncytial virus (RSV) is the main cause of lower respiratory tract infections in infants, the elderly & immunocompromised patients; associated with significant morbidity & mortality in these populations. There are currently no effective licensed therapies available for RSV. hVIVO has the only commercially validated human challenge model available to test the efficacy and effectiveness of your vaccine or antiviral.

Seasonal influenza (“flu”) causes significant morbidity and mortality each year and a pandemic influenza continues to pose a worldwide threat. hVIVO has been studying influenza for over 20 years and been conducting influenza human studies for more than 15 years. for a range of industry, governmental and academic clients, This makes our models the most well-used commercial flu disease models available on the market.

The COVID-19 pandemic has led to a series of rolling lockdowns around the world and caused significant numbers of infections & deaths. Our hVIVO COVID-19 Human Challenge Model (Wuhan, Delta & Omicron) offers drug and vaccine developers a wide range of solutions to speed up the development of their product.

Human metapneumovirus (hMPV) was first identified in 2001 and is a disease that spreads person to person through close contact. The symptoms normally involved usually mirror those of the common cold, however for infants, the elderly, asthmatics and immunocompromised people, the symptoms can be more serious (such as Bronchiolitis, Bronchitis & Pneumonia).

Human rhinoviruses (HRV) are the most commonly isolated viral pathogens in people suffering with ‘the common cold’. HRV infections are known to be an important predisposing factor to conditions such as sinusitis, otitis media, bronchitis and primary pneumonia. At hVIVO we have HRV16 challenge, which may be used to test both prophylactics and therapeutics.

Malaria is a serious and life-threatening, mosquito borne disease. Due to increasing resistance to current antimalarial regimens, new drugs are required as both stand-alone and partner therapies to address a growing unmet medical need. hVIVO has a validated GMP manufactured P. falciparum sporozoite challenge agent to test potential therapeutics in fighting this infectious disease.

Viral infections are reportedly responsible for approximately 65-80% of asthma and 40% of COPD exacerbations and occur despite appropriate treatments including inhaled corticosteroids.

hVIVO can help with respiratory human challenge in both asthma and chronic obstructive pulmonary disease (COPD)

hLAB’s capabilities for custom assay Development, Validation and tech Transfer to FDA, EMA and ICH guidelines according to GCLP ensuring optimised readouts for assays.

Working with global biologistic partners, hLab can provide all your sample collection kit needs to support your field trial studies.

hLAB provides a broad portfolio of serological and infectivity assays for a range of target pathogens . All our assays are optimised for both data integrity and throughput.

hLab offers full molecular services for quantitative viral load assessments, qualitative diagnostic and respiratory virus panel testing as well as bespoke assay development (e.g. SNP allelic PCR development).

hLab offers compound efficacy assessment services to support Discovery and Pre-clinical compound efficacy for anti-viral compounds; post challenge or vaccination assessment of generation of genetic variants and shifts in compound efficacy

hLAB offers vast and complex customized solutions for biomarker analysis through the development and validation of laboratory assays that allow the quantification and characterization of immune responses in clinical trials.